Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;8(2):299-308.
doi: 10.2217/nnm.13.3.

Biotargeted nanomedicines for cancer: six tenets before you begin

Michael S Goldberg  1 , Sara S Hook, Andrew Z Wang, Jeff W M Bulte, Anil K Patri, Fatih M Uckun, Vincent L Cryns, Justin Hanes, Demir Akin, Jennifer B Hall, Nastaran Gharkholo, Russell J Mumper
Affiliations

Biotargeted nanomedicines for cancer: six tenets before you begin

Michael S Goldberg et al. Nanomedicine (Lond). 2013 Feb.

Abstract

Biotargeted nanomedicines have captured the attention of academic and industrial scientists who have been motivated by the theoretical possibilities of the 'magic bullet' that was first conceptualized by Paul Ehrlich at the beginning of the 20th century. The Biotargeting Working Group, consisting of more than 50 pharmaceutical scientists, engineers, biologists and clinicians, has been formed as part of the National Cancer Institute's Alliance for Nanotechnology in Cancer to harness collective wisdom in order to tackle conceptual and practical challenges in developing biotargeted nanomedicines for cancer. In modern science and medicine, it is impossible for any individual to be an expert in every aspect of biology, chemistry, materials science, pharmaceutics, toxicology, chemical engineering, imaging, physiology, oncology and regulatory affairs. Drawing on the expertise of leaders from each of these disciplines, this commentary highlights six tenets of biotargeted cancer nanomedicines in order to enable the translation of basic science into clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sequential barriers and opportunities for targeting a nanomedicine to cancer.
Figure 2
Figure 2
Transport of nanoparticles from the vasculature into the tumor parenchyma and hypoxic core.
See this image and copyright information in PMC

References

    1. Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. J Vasc Surg. 2005;42(1):40–46. - PubMed
    1. Park J-H, Von Maltzahn G, Xu MJ, et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci USA. 2010;107(3):981–986. - PMC - PubMed
    1. Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm. 2011;8(1):143–152. - PMC - PubMed
    1. Agemy L, Friedmann-Morvinski D, Kotamraju VR, et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA. 2011;108(42):17450–17455. - PMC - PubMed
    1. Poon Z, Lee JA, Huang S, Prevost RJ, Hammond PT. Highly stable, ligand-clustered “patchy” micelle nanocarriers for systemic tumor targeting. Nanomedicine (Lond) 2011;7(2):201–209. - PMC - PubMed

Websites

    1. A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer. http://clinicaltrials.gov/ct2/show/NCT01300533?term=NCT01300533&rank=1.
    1. Safety Study of CALAA-01 to Treat Solid Tumor Cancers. http://clinicaltrials.gov/ct2/show/NCT00689065?term=NCT00689065&rank=1.
    1. Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma. http://clinicaltrials.gov/ct2/show/NCT00964080?term=NCT00964080&rank=1.
    1. Safety Study of Infusion of SGT-53 to Treat Solid Tumors. http://clinicaltrials.gov/ct2/show/NCT00470613?term=NCT00470613&rank=1.
    1. National Cancer Institute’s Nanotechnology Characterization Laboratory. http://ncl.cancer.gov/Very informative website that has excellent resources including assay cascades and standard operating procedures for physical/chemical characterization and in vitro and in vivo testing of nanoparticles.

Publication types

LinkOut - more resources